Leading AIDS researchers, backed by the the AIDS Vaccine Advocacy Coalition, called for increased funding to study widespread use of Gilead Sciences' HIV drugs tenofovir and emtricitabine as preventive therapy for those at high risk of the disease. The recommendation came after several setbacks in recent studies aimed at discovering vaccines against HIV infection.

Related Summaries